Yiran Gan 4/4/25 Yiran Gan 4/4/25 Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson’s Disease Read More Yiran Gan 4/4/25 Yiran Gan 4/4/25 Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease Read More Yiran Gan 4/4/25 Yiran Gan 4/4/25 Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology Read More Yiran Gan 4/4/25 Yiran Gan 4/4/25 Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson's Disease Read More Yiran Gan 4/4/25 Yiran Gan 4/4/25 Associations between Plasma Biomarkers and Cognition in Patients with Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: A Cross-Sectional and Longitudinal Study Read More Yiran Gan 4/4/25 Yiran Gan 4/4/25 Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson’s Disease Read More Yiran Gan 4/4/25 Yiran Gan 4/4/25 Plasma Aβ42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment Read More Yiran Gan 4/4/25 Yiran Gan 4/4/25 Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects Read More Yiran Gan 4/4/25 Yiran Gan 4/4/25 Plasma Amyloid Beta and Tau Levels Are Predictors of Post-stroke Cognitive Impairment: A Longitudinal Study Read More Yiran Gan 4/4/25 Yiran Gan 4/4/25 Long-Term Storage Effects on Stability of Aβ1–40, Aβ1–42, and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays Read More Newer Posts Older Posts
Yiran Gan 4/4/25 Yiran Gan 4/4/25 Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson’s Disease Read More
Yiran Gan 4/4/25 Yiran Gan 4/4/25 Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease Read More
Yiran Gan 4/4/25 Yiran Gan 4/4/25 Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology Read More
Yiran Gan 4/4/25 Yiran Gan 4/4/25 Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson's Disease Read More
Yiran Gan 4/4/25 Yiran Gan 4/4/25 Associations between Plasma Biomarkers and Cognition in Patients with Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: A Cross-Sectional and Longitudinal Study Read More
Yiran Gan 4/4/25 Yiran Gan 4/4/25 Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson’s Disease Read More
Yiran Gan 4/4/25 Yiran Gan 4/4/25 Plasma Aβ42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment Read More
Yiran Gan 4/4/25 Yiran Gan 4/4/25 Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects Read More
Yiran Gan 4/4/25 Yiran Gan 4/4/25 Plasma Amyloid Beta and Tau Levels Are Predictors of Post-stroke Cognitive Impairment: A Longitudinal Study Read More
Yiran Gan 4/4/25 Yiran Gan 4/4/25 Long-Term Storage Effects on Stability of Aβ1–40, Aβ1–42, and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays Read More
